S. P. Likitha Rao*1, Anil Middah1, Neeraj Tandan2
1OPJS University, Rajasthan, India
2SARC (Scientific and Applied Research Centre), Hyderabad, India
A B S T R A C T
The aim of present study was to develop renin inhibitor as anti-hypertensive drug. Selective inhibition of the renin has gained attraction as interesting approach to control hypertension and associated cardiovascular risk factors given its unique position in the renin-angiotensin system. Thus it regulates the body’s mean arterial blood pressure. It is required in homeostasis of our body and the enzyme belongs to aspartic proteases family of enzyme converting angiotensinogen to angiotensin 1. Angiotensin has been originally reported as an inactive enzyme. Another enzyme known as angiotensin converting enzyme (ACE) protelytically converts in to angiotensin II, which is responsible for maintaining blood pressure. The major limitation factor in maintaining blood pressure is enzyme conversion of active molecule, which is a rate limiting step. Therefore, Renin is very critical in playing a catalytic role in mediating blood pressure by the Renin-Angiotensin system. The objective of the study is to screen various inhibitors and to design the pharmcophore. In the study MOE was used, a tool for lead discovery. In the paper we report the feasibility of new compounds as a lead in the drug development for Renin inhibitor.
Keywords: Renin- angiotensin system (RAS), pharmacophore model, Docking.